Benjamin Cravatt Net Worth

The estimated Net Worth of Benjamin Cravatt is at least $79.2 mil dollars as of 7 June 2023. Benjamin Cravatt owns over 3,944 units of FibroGen Inc stock worth over $11,494 and over the last 4 years he sold FGEN stock worth over $67,718. In addition, he makes $0 as Director at FibroGen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Benjamin Cravatt FGEN stock SEC Form 4 insiders trading

Benjamin has made over 1 trades of the FibroGen Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 3,944 units of FGEN stock worth $67,718 on 7 June 2023.

The largest trade he's ever made was selling 3,944 units of FibroGen Inc stock on 7 June 2023 worth over $67,718. On average, Benjamin trades about 789 units every 0 days since 2020. As of 7 June 2023 he still owns at least 28,736 units of FibroGen Inc stock.

You can see the complete history of Benjamin Cravatt stock trades at the bottom of the page.

Benjamin Cravatt biography

Dr. Benjamin Cravatt Ph.D. serves as Director of the Company. serves as Director of the Company. Dr. Cravatt is an Associate Editor for Journal of the American Chemical Society and is a co-founder of Activx Biosciences, Abide Therapeutics, and Vividion Therapeutics. He serves on the Board of Directors of Vividion, Boundless Bio, and Autobahn Therapeutics. Dr. Cravatt's honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the RSC Jeremy Knowles Award, the AACR Award for Achievement in Chemistry in Cancer Research, and memberships in the American Academy of Arts and Sciences, National Academy of Inventors, National Academy of Medicine, and National Academy of Sciences. Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute in 1996.

What's Benjamin Cravatt's mailing address?

Benjamin's mailing address filed with the SEC is C/O FIBROGEN, INC., 409 ILLINOIS ST., SAN FRANCISCO, CA, 94158.

Insiders trading at FibroGen Inc

Over the last 10 years, insiders at FibroGen Inc have traded over $188,593,537 worth of FibroGen Inc stock and bought 106,523 units worth $1,309,423 . The most active insiders traders include Rory B Riggs, Thomas B Neff, eJeffrey William Henderson. On average, FibroGen Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,963. The most recent stock trade was executed by Deyaa Adib on 12 June 2024, trading 22,123 units of FGEN stock currently worth $25,884.

What does FibroGen Inc do?

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.

Complete history of Benjamin Cravatt stock trades at FibroGen Inc

FibroGen Inc executives and stock owners

FibroGen Inc executives and other stock owners filed with the SEC include:

• Kin-Hung Yu,
  Chief Medical Officer
• James Schoeneck,
  Chairman of the Board
• Elias Kouchakji,
  Senior Vice President, Clinical Development, Drug Safety and Pharmacovigilance
• Christine Chung,
  Senior Vice President, China Operations
• Pat Cotroneo,
  Chief Financial Officer
• Enrique A. Conterno,
  CEO & Director
• Dr. Elias Kouchakji,
  Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
• Pat Cotroneo,
  Exec. Advisor to CEO
• Suzanne Blaug,
  Independent Director
• Thane Wettig,
  Chief Commercial Officer
• Dr. Mark Eisner M.D., M.P.H.,
  Chief Medical Officer
• Thomas Kearns,
  Lead Independent Director
• Jeffrey Edwards,
  Independent Director
• Rory Riggs,
  Independent Director
• Gerald Lema,
  Independent Director
• Jeffrey Henderson,
  Independent Director
• Maykin Ho,
  Independent Director
• Kalevi Kurkijarvi,
  Independent Director
• Toshinari Tamura,
  Independent Director
• James A. Schoeneck,
  Chairman
• Benjamin Cravatt,
  Director
• Aoife Brennan,
  Director
• Thane Wettig,
  Chief Commercial Officer
• Percy Carter,
  Chief Scientific Officer
• Enrique Conterno,
  Chief Executive Officer, Director
• Dr. John J. Hunter Ph.D.,
  Chief Scientific Officer
• Dr. Michael J. Martinelli,
  Sr. VP of Technical Devel.
• Juan Graham,
  Chief Financial Officer
• Dr. Barry A. Berkowitz Ph.D.,
  Founder
• Jorma Routti,
  Director
• K Peony Yu,
  Chief Medical Officer
• Thomas B Neff,
  Chief Executive Officer
• Mark Eisner,
  EVP, Chief Medical Officer
• Julian N Stern,
  Director
• Frank H Md Valone,
  Chief Medical Officer
• Miguel Madero,
  Director
• Pharma Inc. Astellas,
  
• Juan Graham,
  CHIEF FINANCIAL OFFICER
• Deyaa Adib,
  Chief Medical Officer